— Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team — Westlake Village, CA – March 25, 2025 – NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced the appointment of Dr. Steven L. […]
— Delshad adds broad management and financial expertise to the NeOnc team — Westlake Village, California – March 25, 2025 – NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced that it has appointed the Honorable Jimmy Delshad to its Board […]
— Dr. Chaing Expands NeOnc’s Expertise in Neurosurgery and Biotechnology — Westlake Village, California – March 25, 2025 – NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced that it has appointed Dr. Alan Chiang to its Board of Directors. Dr. […]
Westlake Village, California – March 25, 2025 – NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, announced today that it has appointed Bader Almonawer, Managing Partner at Arabian Group, a provider of insurance solutions, to its Board of Directors. Almonawer brings significant […]
NeOnc’s second concurrent Phase 2 clinical study seeks further safety and preliminary evidence of the biological effects of its lead drug candidate, NEO100™, on certain cancers of the brain and central nervous system. Generated by NeOnc’s patented NEO™ technology platform, NEO100-02™ for meningioma indications is intended to target such tumors that occur in membranes […]
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors NEO212™ completes the initial two cohorts of its Phase 1 study under FDA Investigative New Drug (IND). The study tests the safety of NeOnc’s patented novel drug, NEO212™, which is […]
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status New investment and debt conversion by new and existing investors sets company’s post-money valuation at approximately $220 million, up 214% from previous funding round. Financing supports further expansion of NeOnc’s […]
LOS ANGELES, May 15, 2024 (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from the California Investment Forum (CIF) for its innovations in medical technology related to the treatment of brain and central nervous system diseases. The award was presented to NeOnc by California […]
Los Angeles, CA, April 18, 2023 – NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has appointed Dr. Iyabo Tinubu-Karch to its scientific advisory board as a strategic advisor. Dr. Iyabo Tinubu-Karch The company’s scientific advisory board, now comprised of five global healthcare leaders, provides NeOnc management with valuable guidance and perspectives on […]
Los Angeles, CA, Chicago, IL, London, UK, April 4, 2023 – NeOnc Technologies Holdings Inc., a clinical-stage medical biotechnology company, announced that its CEO, Thomas Chen, MD, Ph.D., has received the Best in Medicine Award from the American Health Council (AHC). As a national collaboration for the advancement of healthcare, the AHC honors with this […]
